Generian is building a first-in-class drug discovery pipeline of small molecule drugs to address the shortcomings of biologics and improve the patient experience by increasing convenience and access.
We strive to discover and develop small molecule therapeutics for diseases with high unmet need—specifically areas dominated by biologics. Oral, small molecule therapeutics are more economically sustainable and allow for treatment titration in a way not possible with antibodies. This approach has the potential to improve the patient experience by increasing convenience and access while reducing cost to payors.